Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$7.26 USD
+0.35 (5.07%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.28 +0.02 (0.28%) 5:56 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.26 USD
+0.35 (5.07%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $7.28 +0.02 (0.28%) 5:56 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
New Strong Sell Stocks for July 15th
by Zacks Equity Research
ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021
Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -14.29% and -60.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aurinia (AUPH) This Earnings Season?
by Zacks Equity Research
Aurinia (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vaxart (VXRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis
by Zacks Equity Research
Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia (AUPH) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Should You Buy Aurinia Pharmaceuticals (AUPH) Ahead of Earnings?
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -27.27% and -50.85%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More
by Zacks Equity Research
Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.
Aerie to Initiate Phase IIb Study for Dry Eye Treatment
by Zacks Equity Research
The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.
Aurinia Completes Final Patient Treatment in Dry Eye Study
by Zacks Equity Research
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.04% and -53.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH
by Kinjel Shah
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 25.00% and -50.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up
by Zacks Equity Research
Aurinia's (AUPH) lupus candidate, voclosporin, met primary endpoint of renal response rate in a late-stage study. An NDA is expected in the first half of 2020.